Chemotherapy Usage Patterns in a US-Wide Cohort of Patients With Metastatic Colorectal Cancer

Analysis of this US-wide mCRC cohort demonstrates that bevacizumab has been more consistently integrated into treatment regimens than anti-EGFR antibody therapies, particularly in first-line therapy. However, treatment choices vary substantially according to specific patient, practice, and provider characteristics.